Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis [PDF]
, 2011 Background: Coadministration of rifampicin dramatically reduces the concentrations of protease inhibitors. A pharmacokinetic study in healthy adults showed that doubling the dose of coformulated lopinavir/ritonavir was able to overcome the inducing ...
Nuttall J. +10 more
core +3 more sources
Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir
Pharmaceuticals, 2014 Poor systemic concentrations of lopinavir (LPV) following oral administration occur due to high cellular efflux by P-glycoprotein (P-gp) and multidrug resistance-associated proteins (MRPs) and extensive metabolism by CYP3A4 enzymes.
Mitesh Patel +4 more
doaj +1 more source
Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen [PDF]
, 2004 Our objective was to study the effect of lopinavir/ritonavir on cerebrospinal fluid (CSF) viral load as part of an antiretroviral combination treatment for HIV-1 infected individuals, and to determine the steady-state concentrations of lopinavir in CSF ...
Fuchs, Dietmar +5 more
core +1 more source
Simultaneous determination of plasma lopinavir and ritonavir by chemometrics-assisted spectrophotometry and comparison with HPLC method [PDF]
Maejo International Journal of Science and Technology, 2013 Chemometrics-assisted spectrophotometry for the determination of two protease inhibitors, lopinavir and ritonavir, in plasma was evaluated. A set of calibration mixtures (calibration set) was designed according to central composite design. The UV spectra
Chutima Matayatsuk Phechkrajang
doaj
Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial
International Journal of Cardiology: Heart & Vasculature, 2021 Introduction: Efficacious therapies are urgently required to tackle the coronavirus disease 2019 (COVID-19). This trial aims to evaluate the effects of atorvastatin in comparison with standard care for adults hospitalized with COVID-19.
Lotfollah Davoodi +7 more
doaj +1 more source
Pharmacokinetic Evaluation of Rifabutin in Combination with Lopinavir-Ritonavir in Patients with HIV Infection and Active Tuberculosis [PDF]
, 2020 Background. Human immunodeficiency virus (HIV)-associated tuberculosis is difficult to treat, given the propensity for drug interactions between the rifamycins and the antiretroviral drugs.
• Rifabutin With Lopinavir-Ritonavir +1 more
core
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores [PDF]
, 2007 Week 48 HIV-RNA treatment response to the protease inhibitor tipranavir co-administered with ritonavir was compared with that of lopinavir co-administered with ritonavir in patients whose baseline isolates had varying lopinavir genotypic mutation scores.
S. L. Walmsley +7 more
core +1 more source
The Rationale for Potential Pharmacotherapy of COVID-19
Pharmaceuticals, 2020 On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first ...
Maha Saber-Ayad +2 more
doaj +1 more source
Personalizing HIV therapy, mission impossible? [PDF]
, 2013 Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core +1 more source
Structural representations with Lopinavir interactions. [PDF]
, 2013 (A) Displaying active site of the PvPM-V Sal-1 (wild type) and its interaction with only known inhibitor lopinavir (red) (B) Displaying active site of the PvPM-V-Ind (mutant) and its interaction with known inhibitor lopinavir (red). The docked lopinavir (
Manmeet Rawat (353685) +4 more
core +1 more source